Nova Patents
EP1925303B1

Use of Angiotensin II type 1 receptor antagonists for the prevention of diabetes

Abstract

This record has no abstract on file.

Term

Term ended

Expired 25 August 2020, 6.1 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

8 claims: 3 independent, 5 dependent

  1. 1
    The use of an angiotensin II type 1 receptor (AT II) antagonist selected from the group consisting of candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention of diabetes in patients exhibiting normal or low blood pressure.
  2. 3
    A pharmaceutical formulation for use in the prevention of diabetes in patients exhibiting normal or low blood pressure, comprising a therapeutically effective amount of angiotensin II type 1 receptor (AT II) antagonist selected from the group consisting of candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan or a pharmaceutically acceptable salt thereof.
  3. 6
    The pharmaceutical formulation for use according to any one of claims 3 to 5, in unit dosage form.
  4. 7
    An angiotensin II type 1 receptor (AT II) antagonist selected from the group consisting of candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan or a pharmaceutically acceptable salt thereof for use in the prevention of diabetes in patients exhibiting normal or low blood pressure.
Independent claims4